Document Actions
Fund
The fund targets companies that are developing commercially promising products and technologies in life sciences, including: pharmaceuticals, biotechnology, information technology and other high technology opportunities that offer venture capital returns.
The fund focuses on seed and early stage companies, but also on pre-seed commercially viable academic projects. The benefits of this early funding means that emerging medical breakthroughs in research and technology businesses can be sustained by sufficient venture capital to optimize their chances of success and ultimately provide revenue to the fund’s investors and the research groups involved. Once these companies are established with seed funding, the Life Sciences Fund Amsterdam will seek to work with other traditional venture capital companies to partner in the effort to advance these technologies.
The close co-operation between the fund and the technology transfer office at the Academic Medical Center Amsterdam (AMC), the University of Amsterdam (UvA), VU University & VU University medical center (VU & VUmc), Sanquin and the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (NKI-AvL), all combined within the Life Sciences Center Amsterdam, enables the fund to facilitate the transfer of technology to the private sector and to provide emerging technology companies and university researchers with vital seed funding and specialized financial and technical assistance. Furthermore, the creation of these new spin-out companies benefits local economic development and has created many new jobs in the region.